Abstract | PURPOSE: EXPERIMENTAL DESIGN: K562 cells were incubated with clofarabine and ara-C either sequentially or simultaneously to evaluate the combination effect on their phosphorylated metabolites. Clonogenic assays were used to determine the cytotoxicity of each agent alone and in combination. Deoxynucleotide analysis was performed to assess the effect of clofarabine on dNTPs. RESULTS: CONCLUSIONS: These findings demonstrate that combination of clofarabine followed by ara-C results in a biochemical modulation of ara-CTP and synergistic cell kill. These studies provide a compelling rationale for clinical trials using this combination regimen for adult and pediatric patients with AML.
|
Authors | Todd Cooper, Mary Ayres, Billie Nowak, Varsha Gandhi |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 55
Issue 4
Pg. 361-368
(Apr 2005)
ISSN: 0344-5704 [Print] Germany |
PMID | 15723262
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Adenine Nucleotides
- Arabinonucleosides
- Cytarabine
- Clofarabine
- Ribonucleotide Reductases
|
Topics |
- Adenine Nucleotides
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Arabinonucleosides
(administration & dosage, pharmacology)
- Clofarabine
- Colony-Forming Units Assay
- Cytarabine
(pharmacology)
- Humans
- K562 Cells
- Maximum Tolerated Dose
- Phosphorylation
- Ribonucleotide Reductases
(metabolism)
- Time Factors
|